ADHerence of ticagrelOr in Real World Patients With aCute Coronary Syndrome
Launched by FROM- FONDAZIONE PER LA RICERCA OSPEDALE DI BERGAMO- ETS · Apr 21, 2017
Trial Information
Current as of May 11, 2025
Completed
Keywords
ClinConnect Summary
Ticagrelor 90 mg twice daily treatment is recommended for 12 months in patients with acute coronary syndrome (ACS) and in patients undergoing coronary revascularization and conservative strategies. Prolongation over 12 months of ticagrelor therapy could be indicated in selected patients; even if with such a prolongation some adverse effects on the treatment could be observed. In the PLATO2 trial, where median duration of exposure to the study drug was 277 days, the suspension of ticagrelor therapy was 7.4% in ticagrelor versus 6% in patients receiving clopidogrel ( P \<0.001). Ticagrelor tr...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult (\>=18 years age) patients
- • Patients discharged from the hospital with a diagnosis of ACS
- • Patients discharged on ticagrelor therapy
- • Patients who have signed an informed consent to study participation
- Exclusion Criteria:
- • Patients taking part in a study with a medical device or experimental drug
About From Fondazione Per La Ricerca Ospedale Di Bergamo Ets
Fondazione per la Ricerca Ospedale di Bergamo ETS is a leading clinical research organization dedicated to advancing medical knowledge and improving patient outcomes through innovative research initiatives. Based in Bergamo, Italy, the foundation collaborates with healthcare professionals, academic institutions, and industry partners to design and conduct high-quality clinical trials across various therapeutic areas. With a strong emphasis on ethical standards and patient safety, the foundation aims to facilitate the translation of scientific discoveries into effective treatments, thereby contributing to the enhancement of healthcare practices and the well-being of the community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Luigi Fiocca, MD
Principal Investigator
ASST Papa Giovanni XXIII
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials